GEN Exclusives

More »

GEN News Highlights

More »
Aug 16, 2007

Parion and Gilead Ink $146M Deal Related to Pulmonary Diseases

  • Parion Sciences and Gilead Sciences entered into an alliance worth $146 million focused on P-680, an epithelial sodium channel (ENaC) inhibitor discovered by Parion.

    Gilead will provide an upfront payment of $5 million for worldwide commercialization rights to P-680 for the treatment of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and non-CF bronchiectasis. The company will also make a $5-million investment in Parion.

    Additionally, Gilead will pay Parion up to $136 million upon achievements of certain milestones. Parion will also be eligible to receive up to double-digit royalties based on potential future product sales.

    The companies also have agreed to collaborate on a research program to identify other ENaC blocker-based drug candidates utilizing Parion’s ENaC-based chemistry platform. Gilead will supply research funding. Parion will perform the IND-enabling studies for P-680 and will transition development responsibilities to Gilead during the Phase I trial period.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?